×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Lung Cancer

Katie Kosko
Investigators at The University of Texas MD Anderson Cancer Center in Houston discovered that adding the PARP inhibitor veliparib to a standard chemotherapy regimen improved overall responses rates (ORR) in patients with relapsed small cell lung cancer (SCLC).
Brielle Urciuoli
The majority of adolescent and young adult (AYA) patients who are diagnosed with cancer are expected to live past the five-year mark, though survival and health outcomes seem to differ by disease type, according to recent research published in the journal Cancer.
Kristie L. Kahl
In a recent survey, researchers from the University of Colorado Denver found a variety of predictors that affect caregiver burden, and how psychological resilience and future interventions can help.
Katie Kosko
Five leading cancer organizations came together to establish four steps that patients of all malignancies can turn to as they navigate their experience.
Brielle Urciuoli
As the field of lung cancer continues to evolve, here are some of the key discussions patients should have with their health care team, according to one expert.
Taylor Bell Duck

Taylor Bell Duck was only 21 when she was diagnosed with lung cancer, a disease that is often stigmatized.
The partners will collaborate to empower the lung cancer community through educational efforts
Kristie L. Kahl
The Food and Drug Administration (FDA) granted a priority review to Keytruda (pembrolizumab) in combination with chemotherapy as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 expression, according to Merck, the manufacturer of the anti-PD-1 agent.
Beth Fand Incollingo
Stand Up To Cancer’s “interception” trials tackle lung and pancreatic disease early, with the goal of preventing progression to advanced stages.
Angelica Welch
An immunotherapy pair looks promising for those with pleural mesothelioma, which is now treated with chemotherapy.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable